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Abstract
Background: Virtual reality (VR) has recently been explored as a tool for neurorehabilitation to enable individuals
with Parkinson’s disease (PD) to practice challenging skills in a safe environment. Current technological advances
have enabled the use of affordable, fully immersive head-mounted displays (HMDs) for potential therapeutic
applications. However, while previous studies have used HMDs in individuals with PD, these were only used for
short bouts of walking. Clinical applications of VR for gait training would likely involve an extended exposure to
the virtual environment, which has the potential to cause individuals with PD to experience simulator-related
adverse effects due to their age or pathology. Thus, our objective was to evaluate the safety of using an HMD
for longer bouts of walking in fully immersive VR for older adults and individuals with PD.
Methods: Thirty-three participants (11 healthy young, 11 healthy older adults, and 11 individuals with PD) were
recruited for this study. Participants walked for 20 min while viewing a virtual city scene through an HMD (Oculus
Rift DK2). Safety was evaluated using the mini-BESTest, measures of center of pressure (CoP) excursion, and questionnaires
addressing symptoms of simulator sickness (SSQ) and measures of stress and arousal.
Results: Most participants successfully completed all trials without any discomfort. There were no significant changes for
any of our groups in symptoms of simulator sickness or measures of static and dynamic balance after exposure to the
virtual environment. Surprisingly, measures of stress decreased in all groups while the PD group also increased the level of
arousal after exposure.
Conclusions: Older adults and individuals with PD were able to successfully use immersive VR during walking without
adverse effects. This provides systematic evidence supporting the safety of immersive VR for gait training in
these populations.
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Background
Parkinson’s disease (PD) is a progressive neurodegenerative
disorder resulting from a loss of dopaminergic cells in the
substantia nigra, and affects over 1 million individuals over
age 65 in the United States and over 7 million worldwide
[1, 2]. Common symptoms of PD are impairments in
balance and gait, rigidity, tremor and bradykinesia.
Although dopamine replacement therapy (DRT) is
commonly prescribed to individuals with PD, pharmaco-
logical interventions, especially in the late course of PD,
become inadequate resulting in a progressive deterioration
in mobility and activities of daily living [3]. In addition,
some of the gait deficits such as stride time variability are
related to the non-dopaminergic lesions [3, 4]. Increasing
evidence supports that task-specific, goal-based motor
skill training promotes neuroplasticity and reduces motor
impairments in individuals with PD [4–8]. Although task-
specific training is often used in the clinic, it may not be
possible to configure the clinical setting to recreate the
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environmental contexts and challenges that patients might
experience in the real world.
In order to address these issues, one recent solution
for providing task-specific gait training in environments
that mimic the real world is through the use of virtual
reality (VR) interventions [9–14]. VR can help to over-
come some of the space and resource limitations found
in traditional clinics while also allowing patients to
repeat the practice of advanced gait skills necessary for
community ambulation [15]. To date, a small number of
studies have investigated gait training for individuals
with PD using non-immersive VR [9, 13, 16, 17]. How-
ever, the coupling between perception and action in
non-immersive VR can be quite different than in the real
world due to an indirect mapping from physical move-
ment to movement of one’s representation in the virtual
environment. To achieve a more natural experience,
immersive VR simulations are often generated using a
head-mounted display (HMD) [11, 12, 14] or room-
scale displays that surround the user such as the CAVE
[18, 19]. In both cases, immersion and presence are
heightened when the motion of visual field is properly
linked with the motion of the head.
Different viewpoints and modes of navigation can be
provided to modify the user’s experience in VR. View-
points are typically separated into first and third person
perspectives [20]. The first person perspective allows the
user to perceive the simulation through the eyes of a
character, whereas the third person perspective forces
the user to observe their character from a distance.
Moreover, two types of navigation are also possible in
VR: egocentric and exocentric navigation [21]. In ego-
centric navigation, the user’s viewpoint is surrounded by
the environment while in exocentric navigation, the user
looks into the environment from outside. Generally, a
first person viewpoint with egocentric navigation pro-
vides more immersion [20] and a more natural visual
experience [22] in VR as it allows the user to be part
of the simulation, rather than an observer. This allows
users to experience a higher degree of presence than
non-immersive environments [23]. Presence is defined
as “the subjective experience of being in one place or
environment, even when one is physically situated in
another” [24]. High presence in immersive VR for re-
habilitation has several benefits [25]. First, users may
“forget” that they are in a training situation. This may
lead to the use of more natural motor patterns and
thereby improve the ecological validity of training.
Second, situations that usually cannot be evaluated in
the clinic, such as walking at night or in inclement
weather, can be simulated. Third, users are able to
view the virtual world in a manner that provides more
natural sensory information [26]. Thus, high presence
in immersive VR has been suggested to be more
effective training approach than non-immersive VR as
it allows provides the user with a more realistic sen-
sorimotor experience.
Despite these benefits, there may be adverse effects of
experiencing VR that might preclude its use in the clinic.
These adverse responses are commonly termed simulator
sickness [27]. Regan and Price explored the effects of a
20 min-exposure to a virtual environment through an
HMD and found that 61% of healthy young participants
experienced some degree of simulator sickness symptoms
[28]. Sharples and colleagues reported that VR exposure
induced more simulator sickness symptoms in healthy
young adults using an HMD than using non-immersive
devices such as a desktop or a projector [29]. In contrast,
a recent study showed that healthy young adults experi-
ence no or minor simulator sickness during neck motion-
controlled VR tasks [30]. This discrepancy is most likely
due to recent advances in technology that have resulted in
inexpensive, high-performing systems that can minimize
adverse responses such as simulator sickness [31].
Moreover, there are concerns that populations such as
older adults or individuals with neurological disorders
may be more likely to have adverse responses to fully
immersive experiences than healthy, young individuals.
There are two common theories to explain the occur-
rence of simulator sickness: (1) sensory conflict theory
and (2) postural instability theory [32]. Sensory conflict
theory suggests that simulator sickness arises from con-
flicts between different senses that cause incompatibility
with stored expectations [33, 34]. For example, conflicts
can occur between the motion that a person perceives
through optic flow and the motion detected by the ves-
tibular and somatosensory systems. These mismatches
may be even more pronounced in older adults due to
sensory processing deteriorations [35] and in individuals
with PD due to impairments in sensory processing and
integration [36–38]. These deficits in sensory processing
and integration in individuals with PD could potentially
generate conflicts between visual and somatosensory
information in a virtual environment, leading to a higher
prevalence of simulator sickness. Postural instability
theory suggests that prolonged postural instability in
unfamiliar situations creates simulator sickness [39, 40].
Specifically, the summation of the body’s natural sway
and the imposed sway created by movement of the virtual
scene may exaggerate postural instability. The reactive
control of this instability may enhance symptoms related
simulator sickness [39]. Since older adults and individuals
with PD have impairments in control of postural stability
[41–43], simulator sickness may be exaggerated in these
populations. However, this has yet to be investigated.
Furthermore, although a few research studies have
successfully used HMDs in individuals with PD for walk-
ing in VR, these studies involved only a short period of
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walking as they were designed to investigate responses
to certain manipulation in VR, not potential adverse ef-
fects associated with extended exposure. Therefore, time
spent in the virtual environment in these studies was
much shorter, approximately total 2–3 min based on the
distance walked and reported gait speed [44–46]. In con-
strast, gait training in the clinic often requires bouts of
walking of at least 20 min [47]. To date, the potential
adverse effects of longer walking experiences in fully im-
mersive VR in older adults and individuals with PD have
not been systematically explored.
Thus, the objectives of this study were to determine if
older adults and individuals with PD can use fully im-
mersive VR using a head-mounted display for a longer
period of walking without adverse effects. To this end,
older adults and individuals with PD were exposed to
an immersive VR experience using a low-cost HMD
(Oculus Rift) during walking on a treadmill. Self-
reported (simulator sickness and emotional state) and
performance (static and dynamic balance) data were
analyzed to determine if there were any adverse effects
associated with exposure to the virtual environment.
Our results provide needed baseline data to support
the potential use of immersive VR using commercial
HMDs as a gait training tool for individuals with PD.
Methods
Participant characteristics
A total of 33 individuals participated in this study
(Table 1) including 11 healthy young adults (HY, 28 ±
7 years, 5 M), 11 healthy older adults (HO, 66 ± 3 years,
3 M), and 11 individuals with Parkinson’s disease PD
(65 ± 7 years, 3 M). Participants were included in the
study if they were able to walk for 30 min on a treadmill,
had a Montreal Cognitive Assessment (MoCA) score
between 19 and 30, which corresponds to having no more
than mild cognitive impairment [48], and had no other
neurological disorders. Participants with PD were classi-
fied as modified Hoehn and Yahr (mH&Y) stage 1–3 with
an average stage of 2 ± 1, and had Movement Disorder
Society Unified Parkinson’s Disease Rating Scale (MDS-
UPDRS) part III mean motor scores of 17 ± 8 while on
medication (Table 2). Nine of the PD participants con-
sumed their medication upon arrival to the laboratory
and two were unable to change their medication schedule.
The MoCA score from one participant with PD was lost
due to a technical problem, and therefore the reported
MoCA scores for the PD group only included 10 partici-
pants. Study procedures were approved by the Institutional
Review Board at the University of Southern California and
all participants provided written, informed consent before
testing began. All aspects of the study conformed to the
principles described in the Declaration of Helsinki.
Experimental protocol
The experimental protocol involved a set of clinical
exams, a 20-min walking period, and a set of pre/post
evaluations (Fig. 1). For participants with PD, we began
by measuring the motor sub-score of the MDS-UPDRS
as a measure of motor dysfunction [49]. Next, or first
for participants without PD, we measured self-selected
walking speed using the 10 m walk test as it is a valid
and reliable measure for assessing functional community
ambulation in individuals with PD and older adults
[50, 51]. We then performed baseline measures of dynamic
balance using the Mini-Balance Evaluations Systems Test
(Mini-BESTest), a 14-item balance assessment for dynamic
balance and gait, which has been shown to be reliable for
assessing balance disorders and fall risk in individuals with
PD [52]. The Activities-Specific Balance Confidence (ABC)
Scale was used to assess each participant’s overall confi-
dence in walking without falling or feeling unsteady [53].
Quantitative assessments of each individual’s level of static
postural sway were performed by measuring their center of
pressure (CoP) excursion for two, 30 s trials of quiet stand-
ing; one trial with their eyes open and one with their eyes
closed. Participants were asked to place their feet shoulder-
width apart while standing on two force platforms (Bertec,
USA), and to stand as still as possible while looking straight
ahead. Anteroposterior (AP) and mediolateral (ML) excur-
sions of the CoP were sampled at 1000 Hz.
Baseline levels of symptoms associated with simulator
sickness were determined using the Simulator Sickness
Questionnaire (SSQ) [54]. The SSQ includes 16 questions
related to simulator sickness and, by administering pre-
and post-test assessments, allowed us to detect changes
in symptoms of nausea, oculomotor discomfort or disorien-
tation due to exposure to the immersive virtual environ-
ment. Participants answered each of the 16 questions based
on the severity of symptoms they experienced using a 4-
point scale from ‘none’ to ‘severe’ (0–3). The point value for
each question was summed for corresponding subcategor-
ies (Nausea, Oculomotor, and Disorientation), then each
subcategory was multiplied by weights of 9.54, 7.58, and
13.92 for Nausea, Oculomotor, and Disorientation, re-
spectively [54]. All subcategories were then summed
Table 1 Participant demographics
HY HO PD
Total participants 11 11 11
Age 28 ± 7 66 ± 3 65 ± 7
Gender 5 Male 3 Male 3 Male
MoCA 29 ± 1 27 ± 2 26 ± 3
(for 10 participants)
ABC 96 ± 5 87 ± 11 74 ± 2
10 m walk test (m/s) 1.34 ± 0.19 1.08 ± 0.34 1.16 ± 0.18
Treadmill speed (m/s) 1.22 ± 0.30 1.00 ± 0.30 0.98 ± 0.27
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and multiplied by 3.74 to generate a total score with a pos-
sible range of 0–235.6 [54]. A cutoff score of 15 was used
to determine if participants experienced significant
simulater sickness after exposure as it represents the
75th percentile of scores for a wide range of standard
virtual reality simulators [54]. Similarly, cutoff scores of
9.5, 15.2, and 0 were used for the Nausea (N), Oculomotor
(O), and Disorientation (D) subscales to determine if indi-
vidual sensory domains were differentially affected by ex-
posure to the virtual environment [54]. The SSQ has been
shown to be reliable in healthy adults (split-half correl-
ation r = 0.80) [55] using split-half reliability rather than
test-re-test reliability due to potential habituation or adap-
tation effects across repeated tests.
Lastly, we assessed baseline mood state using the Stress
Arousal Checklist (SAC) [56]. The SAC is used to
characterize mood, specifically stress and arousal re-
sponses, in a variety of situations. Thus, it was used to
determine if there were adverse changes in mood due
to the VR experience. The SAC contains 33 stress- and
arousal-related questions and participants answered each
question according to a 4 point scale from ‘definitely do
not feel’ to ‘definitely feel’ (1–4) [56]. Each answer was
multiplied by an appropriate weight and the values were
summed. Scores for stress ranged from −13.65 to 23.4
with higher scores indicating more stress. Scores for
arousal ranged from −9.91 to 17.66 with higher values cor-
responding to increased arousal. The split-half reliability
coefficients for both stress and arousal were r = 0.80 and
0.82, respectively in healthy adults [57]. The SAC was
tested using split-half reliability measures instead of test-
re-test metrics because of the transient nature of one’s
emotional state [58].
Next, participants walked on the treadmill at the speed
that was measured during the 10 m walk test to deter-
mine if they were comfortable using this speed for the
duration of the treadmill trials. Thirteen participants
(3 HY, 5 HO and 5 participants with PD) chose to re-
duce the speed of the treadmill below their 10 m
walk speed either because they were not familiar with
walking on a treadmill or because they perceived the
Table 2 Characteristics of the participants with PD
Sex Age Years since
diagnosis




M 71 32 - 19 2 1 R1 L1 - 94
F 71 10 28 10 1.5 0 0 0 0 84
F 76 9 30 26 1.5 0 0 0 1 89
F 74 3 27 15 3 1 0 R, L1 0 73
F 61 3 29 22 1.5 1 R, L1 0 0 88
F 62 3 28 30 2.5 2 R, L1 0 0 92
M 56 5 26 8 1.5 0 R, L1 0 0 88
F 60 1 20 7 1 0 0 0 1 64
M 69 4 25 14 1.5 0 0 R1 0 53
F 60 2 21 28 3 0 0 0 0 25
F 55 5 26 13 2 0 0 R2, L1 1 66
UE Upper extremity, LE Lower extremity, R Right, L Left, FOG Freezing of Gait
aScore from question 2.13 (Freezing) in the MDS-UPDRS
bThe first letter represents the side of the limb and second number represents the MDS-UPDRS score
Fig. 1 Experimental protocol. Pre-test evaluation involved a set of
clinical assessments (MDS-UPDRS for the PD group, mini-BESTest,
10 m walk test, MoCA), static postural stability measures (CoP during
eyes open and closed) and questionnaires (SSQ, SAC). The test
consisted of walking for a total of 20 min with breaks taken every
5 min for participants to complete a short symptom checklist and
for measures of blood pressure (BP) to be monitored. Post-test evaluation
involved an additional set of clinical assessments (mini-BESTest, 10 m walk
test), static postural stability measures and questionnaires (SSQ, SAC, PQ)
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speed on the treadmill to be faster than over-ground
(Table 1). For all other participants, the speed determined
from their 10 m walk was used for all treadmill trials.
Virtual reality exposure
Participants viewed our immersive virtual environment
via a head-mounted display (Oculus Rift Development
Kit 2, Oculus VR, LLC) while walking on the treadmill.
The display was calibrated to each participant’s mea-
sured inter-pupillary distance and horizontal field of
view using a calibration sequence provided by Oculus.
After calibration, participants donned the HMD and
walked for four, 5 min bouts on the treadmill (Bertec
Fully Instrumented Treadmill, USA). After each 5-min
bout, participants were given a 1-min rest break during
which they completed a Short Symptom Checklist [59]
to report any symptoms of simulator sickness. The
checklist is a 6-item questionnaire adapted from the
SSQ [59]. Blood pressure and heart rate were also mea-
sured during the rest break.
The virtual environment shown on the HMD was de-
veloped using Sketchup (Trimble Navigation Limited,
USA), and the participants’ interaction with the environ-
ment was controlled using Vizard (WorldViz, USA). The
virtual environment consisted of a cityscape with build-
ings, animated avatars, and an 800 m straight sidewalk
(Fig. 2). The avatars were added to provide a dynamic
element to the virtual environment, and they were the
only animated features of the environment. Movements
through the environment were constrained to the for-
ward direction, but participants were able to freely look
around the scene while walking. The environment did
not include any turns, doorways, or crossing of thresh-
olds. The velocity of the simulation was synchronized to
the speed of the treadmill, and the orientation of the
participants’ viewpoint was synchronized with head
orientation using an inertial measurement unit embed-
ded in the HMD. The environment was updated at
refresh rate ~60 frames per second and the simulation
was run on a desktop computer with 8 GB RAM, an
Intel Core i7 CPU, and an NVIDIA GeForce GTX 770
GPU. The HMD had a resolution of 960 × 1080 pixels
for each eye, a refresh rate of up to 75 Hz, a 100° field of
view, and a mass of approximately 450 g.
Post-test assessments
Following the four walking bouts, participants were
re-assessed using the 10 m walk test, mini-BESTest, and
measures of CoP excursion to determine if exposure to
the virtual enevironment resulted in any motor distur-
bances. Participants also completed a series of post-test
questionnaires including the SSQ, SAC, and the
Presence questionnaire (PQ, version 2.0). The PQ was





Fig. 2 Representative images of the virtual environment. The environment
consisted of a cityscape including buildings, avatars and a 800 m pedestrian
path. A first person views (a) up, (b) front, (c) left, and (d) right
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virtual environment, or “presence” [24]. The PQ con-
tained 19 virtual experience-related questions (e.g.
‘How closely were you able to examine objects in the
virtual environment?’). Participants described their
degree of presence using a scale from ‘not at all’ to
‘extremely’ (1–7). The answers were summed yielding
a possible range of 19–133. Subscales of the PQ in-
cluded the following: Involvement/Control (score range:
10–70); Visual fidelity (2–14); Adaptation/Immersion
(4–28); and Interface quality (3–21) [60]. The reliability
of the PQ in healthy young adults was established using
internal consistency measures of reliability (Cronbach’s
Alpha), which yielded an alpha of 0.88 [24].
Data analysis
Mean sway area was computed from the COP data in
Matlab (Natick, MA) using the method described in
Duarte and Zatsiorsky [61]. Briefly, the net CoP was
computed from a weighted average of the individual
CoPs from each force platform. The net CoP trajectory
was then fit with a 95% confidence ellipse, and the area
of this ellipse was used to quantify sway area.
Statistical analyses
All statistical analyses were performed in Matlab. A two-
way, repeated measures ANOVA was performed to test for
an effect of group (HY, HO, or PD) or time (Pre- and Post-
test) on the SSQ, SAC, mini-BESTest, and 10 m walk. A
three-way, repeated measures ANOVA was performed to
test for an effect of group, time, or vision condition (EO and
EC) on CoP sway area. A one-way ANOVA was performed
to test for an effect of group on the PQ. Significance was
assessed at the p < 0.05 level. If there were significant main
effects or interactions, post hoc comparisons were per-
formed using Tukey’s Honest Significant Difference.
Results
Simulator sickness
Simulator-related sickness symptoms were not enhanced
after the VR exposure in any groups (Fig. 3). There was
a significant main effect of group (F(2, 30) = 6.05, p <
0.01) on the total simulator sickness score, but no effect
of time (F(1, 30) = 0.447, p = 0.51) or interaction between
group and time (F(2, 30) = 0.691, p = 0.51). Post hoc
analysis revealed that the PD group presented higher
SSQ scores overall compared to HY (p < 0.01) and HO
groups (p < 0.01). The average SSQ scores were 8.3 ±
10.5, 6.5 ± 13.0, and 27.5 ± 22.5 for HY, HO, and PD
groups, respectively. All participants completed four
bouts of walking and no participants verbally reported any
symptoms of simulator sickness. Overall, the individual
analysis of score changes between pre- and post-test
showed that two participants from the HO group and
one participant from PD group had post-test scores
that were at least 15 points higher than their pre-test
scores, which is a cut-off score of having simulator
sickness [54]. This suggests that there may be a small
fraction of these populations who may not be good
candidates for locomotor training in VR.
Analysis of the sub-scores of the SSQ indicated that
no specific domains of simulation-related sickness were
changed by VR exposure. There was a main effect of
group (F(2,30) = 7.75, p < 0.01) on the level of nausea
(N), but no effect of time (F(1,30) = 0.328, p = 0.57) nor
interaction between time and group (F(2,30) = 0.245, p =
0.78). Post hoc analysis showed that the PD group had
higher scores than HY (p < 0.01) and HO group (p <
0.01). The average N scores were 5.8 ± 7.4, 6.1 ± 11.2,
and 20.8 ± 18.3 for HY, HO, and PD groups, respectively.
Individual analysis showed that 3 participants in each
group increased their N scores above the cutoff of 9.5.
There were no main effects of group (F(2,30) = 2.93, p =
0.069), time (F(1.30) = 0.223, p = 0.64), nor interaction
between time and group (F(2,30) = 3.10, p = 0.06) on
oculomotor (O) scores, and only 2 HO participants
increased the O scores above 15.2. There was a main
effect of group (F(2,30) = 5.87, p < 0.01) on disorientation
(D) scores, but no effects of time (F(1,30) = 0.116, p =
0.74) or interaction between time and group (F(2,30) =
0.283, p = 0.76). Post hoc analysis showed that the score
of PD group was higher than HY group (p < 0.01) and
HO group (p < 0.01). The average D scores were 6.5 ±
13.6, 4.4 ± 12.4, and 28.5 ± 29.3 for HY, HO, and PD
groups, respectively. Individual analysis revealed that 1
HY, 3 HO and 3 PD increased the D scores above 0.
We found no main effects of group (F(2, 30) = 0.892, p =
0.42) or time (F(2, 60) = 0.353, p = 0.70) or interaction
between group and time (F(4, 60) = 0.823, p = 0.52) for the
short symptom checklist. This indicates that all groups
rapidly acclimated to our virtual environment.
Center of pressure (CoP)
Postural sway, as measured by CoP area, was not affected
by VR exposure in any of our groups (Fig. 4). There was a
significant main effect of group (F(2,60) = 6.51, p < 0.01)
on sway area, but no effect of time (F(1,60) = 1.47, p =
0.23), vision condition (F(1,60) = 0.178, p = 0.68) nor inter-
action between group and time (F(2,60) = 0.809), p = 0.45),
between time and condition (F(1,60) = 0.0735, p = 0.79),
between group and condition (F(2,60) = 0.050, p = 0.95),
or among group, time and condition (F(2,60) = 0.319, p =
0.73). Specifically, post-hoc analyses revealed that the sway
area in the PD group was greater than the sway area in
the HY group (p < 0.05). Average sway areas were 109 ±
60, 168 ± 125, and 572 ± 1010 mm2 for HY, HO and PD,
respectively. The data indicate that static postural
control measured by CoP sway was not affected by the
VR exposure.




























Fig. 3 Pre- (dark gray bar) and post-test (white bar) average simulator sickness questionnaire total score and sub-category scores with standard
deviation. Asterisks represent statistical significance (**: p < 0.01, ***: p < 0.005). a Average total score of SSQ. b Average Nausea score. c Average
Oculomotor discomfort score. d Average Disorientation score
Fig. 4 CoP sway area. Pre- (black bar) and post-test (dark gray bar) during eyes open (EO) and pre- (light gray bar) and post-test (white bar) during
eyes closed (EC). Vertical bars represent standard deviations. Asterisks represent statistical significance (*: p < 0.05)
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Clinical assessment
Interestingly, both mini-BESTest scores and self-selected
gait speed improved after VR exposure. There were sig-
nificant differences of group (F(2,30) = 11.0, p < 0.001)
and time (F(1,30) = 7.58, p < 0.01) on mini-BESTest
scores, but no significant interaction between group and
time (F(2,30) = 1.96, p = 0.16). Post hoc analysis showed
PD (p < 0.001) and HO (p < 0.01) groups had lower mini-
BESTest scores than the HY group. Moreover, the post-
performance improved compared to the pre-performance.
The average mini-BESTest scores were 28 ± 1, 23 ± 4,
and 21 ± 4 for pre-test HY, HO, and PD groups and 28
± 1, 25 ± 3, and 23 ± 4 for post-test HY, HO, and PD
groups, respectively. We found a significant effect of
group (F(2,30) = 5.33, p < 0.05) and time (F(1, 30) = 5.99, p
< 0.05) on gait speed, but no significant interaction (F(2,30)
= 0.60, p = 0.55). The speed of the HY group was signifi-
cantly faster than the HO group (p < 0.05) and, across all
groups, participants walked significantly faster after ex-
posure, where baseline speed was 1.34 ± 0.19 m/s, 1.08 ±
0.34 m/s, and 1.16 ± 0.18 m/s for HY, HO, and PD, re-
spectively and post-exposure speed was 1.42 ± 0.17 m/s,
1.12 ± 0.27 m/s, and 1.20 ± 0.18 m/s for HY, HO, and PD,
respectively.
Stress-arousal
We found significant effects of exposure to the virtual
environment on both stress and arousal. For the level of
stress, all groups presented less stress after exposure to
the environment. The stress level was significantly af-
fected by time (F(1,30) = 7.07, p < 0.05), but not affected
by group (F(2,30) = 1.08, p = 0.35), and there was no
interaction between group and time (F(2,30) = 3.13, p =
0.058). Post hoc analysis of time effect showed that post-
stress score was significantly lower than pre-stress score,
where the total stress scores were −9 ± 4 and −11 ± 3 for
pre- and post-test, respectively. For the level of arousal,
the PD group showed a larger increase after exposure
relative to either of the healthy groups. There were no
main effects of time (F(1,30) = 2.30, p = 0.14) or group
(F(2,30) = 0.175, p = 0.84) on arousal scores, but there
was a significant interaction between group and time
(F(2,30) = 4.67, p < 0.05). Post hoc analysis for the inter-
action between group and time showed that the score
change between pre- and post-exposure was greater in
the PD group compared to the HY and HO groups. The
absolute score changes of the level of arousal were 3 ± 2,
4 ± 4, 8 ± 7 for HY, HO, and PD groups, respectively.
Presence
Healthy young adults experienced a higher sense of pres-
ence in the virtual space than healthy older adults (Fig. 5).
There was a main effect of group on the level of perceived
presence in the virtual environment (F(2,30) = 3.77, p <
0.05). Specifically, the HO group had significantly lower
scores than the HY group (p < 0.05). When examining the
sub-categories of the PQ, we found a main effect of group
on the Involvement/Control score (F(2,30) = 4.79, p <
0.05), with the HY score being higher than HO (p < 0.05).
This higher Involvement/Control score in the HY group
relative to the HO groups is the likely source of the ob-
served differences in overall presence. Lastly, there were
no effects of group on Visual Fidelity (F(2,30) = 1.61, p =
0.22), Adaptation/Immersion (F(2,30) = 3.19, p = 0.056), or
Interface Quality (F(2,30) = 0.149, p = 0.86). The presence
score for the PD group was not significantly different from
either of the healthy groups.
Discussion
The aim of this study was to evaluate if age or Parkinson’s
disease affects the safety of using immersive VR with a
head-mounted display for extended periods of walking.
Despite emerging uses of VR in the context of gait rehabili-
tation for individuals with PD [9, 13, 16], previous studies
have not explicitly investigated potential negative afteref-
fects of using fully immersive VR. Our study revealed that
symptoms of simulator-related sickness and static and
dynamic postural control were not affected by exposure
to a fully immersive environment for the majority of
participants. Thus, older adults and individuals with
mild to moderate PD are capable of using immersive
VR for a total of 20 min of walking practice in 5-min
bouts with minimal negative aftereffects.
Simulator sickness is one of the most common side
effects of using VR, but we found that our virtual simula-
tion elicited only minor changes in symptoms of nausea,
oculomotor discomfort, or disorientation. Simulator sick-
ness is an undesirable side effect of VR experiences when
using HMDs for flight simulations or 3D video games
[27–29], and is also an unwanted side effect for VR-based
rehabilitation interventions. We found that overall SSQ
scores were higher in our PD group, but this is likely a
side-effect of medication [62] or an expression of non-
motor symptoms of PD such as nausea [63] given that
these symptoms were present before exposure to the
virtual environment. The majority of participants in all of
our groups successfully completed a total of 20 min of
walking in the virtual environment without increasing the
severity of simulator sickness. This indicates that age and
the presence of PD have negligible influence on the feasi-
bility of using fully immersive virtual reality with recent,
commercial HMDs.
Postural disequilibrium is another common side effect
of VR [64], but this was not observed in any of our test
groups. Overall, larger and more variable sway area dur-
ing quiet standing was observed in the PD group relative
to the HY and HO groups. This indicates that static pos-
tural stability was inherently lower in the PD group in
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agreement with previous work [41, 42]. The HO and PD
groups had lower mini-BESTest scores than the HY
group indicating that the HO and PD groups were more
dynamically unstable than the HY group due to the ef-
fects of age [65] and/or Parkinson’s disease [66]. How-
ever, neither sway area nor mini-BESTest scores was
adversely affected by exposure to the current simulation.
Interestingly, we observed a significant increase in the
mini-BESTest scores after VR exposure, suggesting that
dynamic postural control may have improved. However,
since the increase in the score did not reach the minimal
detectable change (MDC of mini-BEST for PD = 5.52
[67]), this improvement may not have been meaningful.
In summary, these findings indicate that postural dis-
equilibrium is not a concern after walking in our
simulation.
An alternative hypothesis for the lack of negative ef-
fects in our PD group is that any sensory deficits present
in this group may have caused them to be less prone to
sensory mismatch-induced simulator sickness. In other
words, if there is incongruence between visual,
vestibular, and proprioceptive information, the resulting
mismatch signal may be underweighted and therefore
have little influence on perceptions of postural stability.
One way to determine the likelihood of this explanation
would be to compare the effects of an imposed sensory
mismatch on symptoms of simulator sickness in individ-
uals with PD who have known sensory deficits. If these
individuals prove to be less prone to symptoms of simu-
lator sickness than healthy controls, then this would
provide support for the hypothesis that sensory mis-
matches are down-weighted in this population.
We also found that individuals with PD were more
emotionally aroused post-exposure compared to HY and
HO groups, and participants in all groups were less
stressed after VR exposure. It is well-established that the
level of arousal increases immediately after aerobic exer-
cise in healthy younger adults [68–70] and healthy older
women [71]. This increase in the level of arousal may
also have occurred in the PD group due to the exertion
associated with the clinical assessments and subsequent
walking bouts. Alternatively, medication may have played a
a
b
Fig. 5 Average presence questionnaire scores are shown with individual scores. a Average total score. b Average sub-category scores; Involvement/
Control, visual fidelity, adaptation/Immersion and interface quality for HY (dark gray bar), HO (light gray bar), and PD (white bar). Vertical bars represent
standard deviations. Asterisks represent statistical significance (*: p < 0.05)
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role in the increased levels of arousal. The pre-SAC was
completed immediately after medication was consumed
and the post-SAC was completed after approximately 2 h.
Therefore, it is quite possible that medication played a role
in the increased level of arousal post-test. The decreased
stress level observed after VR exposure may result from the
participants initially feeling stressed and anxious about the
unknown experience involved with virtual reality. Then, as
the VR exposure progressed, they may have become more
relaxed after acclimating to the system. Given these results,
we believe that it is important for future studies to evaluate
the potential for VR and game-based interventions to im-
prove aspects of mood and psychological state in addition
to changes in physical performance.
Relevance to proposed theories of simulator sickness
Our results also provide some insight into the robustness of
previously proposed theories of simulator-related sickness.
Although individuals with PD had significantly higher sway
area and lower mini-BESTest scores than age-matched con-
trols, this did not increase their likelikehood of simulator
sickness. This suggests that the postural instability theory is
not a sufficient explanation of the cause of simulator sick-
ness as this theory would predict that simulator sick-
ness should scale with postural instability. In contrast,
our results provide little evidence regarding the poten-
tial contribution of the sensory conflict theory to simu-
lator sickness. The visual scene in our simulation was
designed to be congruent with the user’s locomotor be-
havior as the speed of translation through the simulated
environment was matched to the participants’ walking
speed. This congruency may have minimized simulator-
related sickness and would be consistent with the work
of Jaeger and Mourant who found that dynamic walking
in VR reduces simulator-related symptoms compared
to a static simulation in younger adults [72]. However,
it is important to note that we did not measure possible
deficits in sensory integration for our participants.
Therefore, it may be possible that they simply did not
have sufficient deficits in sensory integration to generate
simulator sickness via sensory conflict.
With recent technological advances, the availability
and practicality of hardware and software for VR-based
interventions has improved significantly compared to
even a few years ago. The virtual simulation used in this
study was able to maintain framerates of approximately
60 frames per second, had a wide field of view, and was
capable of responding to changes in head roll, pitch, and
yaw. In contrast, previous studies that used immersive
VR with HMDs reported that they maintained approxi-
mately 20–40 frames per second, which can induce high
delay and lag between the movement and the simulation
[29]. This may have caused significant simulator sickness
in those studies and would likely interfere with the
immersive experience. Thus, if a virtual simulation can
maintain high update and tracking rates, the occurrence
of side effects from using VR can be minimized.
Study limitations
There were few limitations in this study. First, to better
generalize our results, future studies including a larger
range of disease severity and a larger sample size that is
more representative of the PD population are needed. Our
study included more women than men in the HO and PD
groups, and considering the higher prevalence of PD in
men [73], future studies should reflect this prevalence bias
in their study sample. Second, the questionnaires used in
our study have only been validated in healthy adults, and
therefore further research is warranted to establish the psy-
chometric properties of these questionnaires in individuals
with PD. Likewise, the SSQ cutoff score that we used to es-
tablish a threshold for simulator sickness has only been
established in healthy younger adults. We expected to see
higher SSQ scores in older adults and individuals with PD
due to the possibility that they might have an impaired abil-
ity to resolve sensory conflicts and maintain postural stabil-
ity. However, we found that only a few participants had
SSQ scores higher than 15, and no participants verbally in-
dicated that they had symptoms of simulator sickness.
Nevertheless, future studies should establish an appropriate
SSQ cutoff score for older adults and individuals with PD.
We should also note that our VR task was not specifically
designed to challenge the known gait-related sensorimotor
deficits of individuals with Parkinson’s disease, and as a re-
sult, this may have contributed to the lack of adverse effects
observed in our study. The performance of more challen-
ging walking tasks such as turning, obstacle negotiation, or
passing through doorways is known to be impaired in indi-
viduals with PD [9, 74, 75]. It remains to be seen if these
impairments, when combined with performance of similar
tasks in a virtual environment, influence the likelihood of
observing simulator-related sickness symptoms. Moreover,
since practicing these types of walking tasks are likely to
have the greatest clinical utility, future studies should con-
tinue to carefully investigate the safety and feasibility of
using fully immersive VR for clinical gait training.
Conclusions
In summary, the aim of our study was to determine if
age or pathology play a role in the observation of nega-
tive physiological and psychological effects after using
immersive VR. We found that 20 min of walking in an
immersive environment using the Oculus Rift did not
induce simulator-related sickness, or alterations in static or
dynamic postural control. This provides a foundation for
future studies exploring novel and innovative approaches to
simulate real-world challenges using immersive virtual
reality while increasing immersion during gait training.
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